Browse the evidence

Bariatric surgery induces rapid hormonal changes (increased GLP-1, PYY, decreased ghrelin) and bile acid signaling that drive early satiety and metabolic improvements, independent of caloric restriction.

Bariatric surgery works by changing your body's hormones, not just by making your stomach smaller. You will likely feel full faster and have less hunger due to increased GLP-1 and PYY and decreased ghrelin. This biological shift supports your ability to stick to dietary changes.

Enobosarm increases lean body mass but fails to deliver consistent, clinically meaningful functional gains (e.g., stair-climb power) in cancer cachexia patients, leading to regulatory rejection.

Enobosarm was tested for cancer cachexia and successfully increased muscle mass, but it did not improve physical function enough to gain FDA approval. This highlights that muscle size alone does not guarantee functional improvement in sick populations.

S-309309, a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2), demonstrates acceptable safety and tolerability in healthy adults with or without obesity, with no clinically meaningful differences in pharmacokinetics between obese and non-obese individuals.

S-309309 is an experimental oral medication that inhibits MGAT2 to potentially aid weight management. Early trials show it is safe and well-tolerated in both obese and non-obese adults, with no significant drug interactions or cardiac effects observed at tested doses. It is not yet approved for general use.

Bariatric surgery significantly reduces the incidence of obesity-associated cancers and cancer-specific mortality compared to non-surgical controls.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing cancer risk. Discuss surgical options with a specialist if lifestyle changes are insufficient.

Obesity is a chronic disease characterized by complex abnormalities in body weight regulation, and weight-related stigmatization is a key barrier to effective care.

Healthcare providers should treat obesity as a chronic disease, not a moral failing. Avoid stigmatizing language to build trust and encourage patients to seek and adhere to treatment.

High cardiorespiratory fitness (CRF) mitigates or eliminates the 'obesity paradox' in heart failure, meaning overweight patients with high CRF do not have better survival than normal-weight patients with low CRF.

For heart failure patients, being overweight is not inherently protective if you are unfit. High cardiorespiratory fitness (CRF) is the key determinant of survival. Focus on improving your fitness through exercise (like the 6-minute walk test or CPX) rather than just focusing on BMI, as high fitness eliminates the 'obesity paradox' survival advantage.

Tirzepatide improves renal outcomes, including reducing the risk of macroalbuminuria and slowing the decline in estimated glomerular filtration rate (eGFR), in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about kidney health, tirzepatide not only helps control blood sugar and weight but also offers significant protection for your kidneys, reducing the risk of serious renal complications compared to insulin therapy.

Use of GLP-1 receptor agonists is not associated with an increased risk of gastrointestinal cancers and may be associated with reduced risks of colorectal and liver cancers.

Current evidence from large randomized trials indicates that GLP-1 receptor agonists do not increase the risk of gastrointestinal cancers. In fact, they may be associated with a reduced risk of colorectal and liver cancers, particularly in older and obese patients. While these findings are reassuring, cancer was often a secondary endpoint, so long-term monitoring remains important.

The indiscriminate use of tirzepatide for aesthetic purposes and the circulation of unregistered products significantly increase the risk of severe adverse events, including gastrointestinal issues, pancreatitis, and renal failure, while compromising public health surveillance.

Using tirzepatide without a doctor's supervision, especially for aesthetic reasons, carries serious risks like pancreatitis and kidney failure. Unregistered versions from informal markets may be fake or unsafe. Always use this medication under medical guidance with a legitimate prescription.

Disruption of the paracrine regulatory network within pancreatic islets—specifically the loss of somatostatin-mediated inhibition of glucagon and insulin-mediated suppression of glucagon—exacerbates hyperglycemia in Type 2 Diabetes.

Managing diabetes effectively requires looking beyond just insulin levels. If you have Type 2 Diabetes, your body's internal hormonal balance—specifically the signals that tell your liver to release sugar (glucagon) and the signals that tell it to stop (somatostatin)—may be broken. This means that even if you are managing insulin, your blood sugar might remain high because your body is still receiving 'release sugar' signals it shouldn't be. Modern therapies increasingly target these other hormones to restore the full balance.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not improve upper-body maximal strength (1-RM bench press) compared to placebo.

Do not take PEA expecting to get stronger. The study found that people taking the placebo actually got slightly stronger in their bench press than those taking PEA. PEA is useful for pain and power, but not for maximal strength.

Pre-sleep protein supplementation (20g or 60g bolus) does not improve performance, body composition, or recovery in British Army recruits undergoing basic training.

If you are undergoing intense military-style or high-volume training, taking 20-60g of protein right before bed will not give you extra strength, muscle, or recovery benefits compared to just eating enough protein throughout the day. Focus on total daily intake and training quality instead of specific supplement timing.

Ingesting 90g of glucose before and after resistance training does not augment ribosomal RNA accumulation or ribosome biogenesis markers in moderately trained young adults.

If you are moderately trained, adding 90g of glucose around your resistance training sessions (before and after) does not appear to boost muscle building signals (ribosome biogenesis) beyond what you get from protein and the training itself. You can likely skip the specific glucose timing strategy without losing potential hypertrophic benefits, focusing instead on total protein and training consistency.

In patients with Type 2 Diabetes Mellitus, paracrine signaling in the adult muscle stem cell niche is activated, specifically through the upregulation of the PDGF–miR-501 pathway.

This research identifies a specific molecular pathway (PDGF-miR-501) that is overactive in the muscle stem cell niche of people with Type 2 Diabetes. This activation might contribute to muscle health issues. While this paper doesn't offer a treatment, it highlights a potential target for future therapies aimed at restoring normal signaling in the muscle niche to improve muscle health in diabetic patients.

Bariatric surgery procedures involving duodenal exclusion (Roux-en-Y gastric bypass and biliopancreatic diversion) achieve sustained Type 2 Diabetes remission rates exceeding 60% at 8 years, significantly outperforming adjustable gastric banding.

For patients with severe obesity and Type 2 Diabetes, Rou-en-Y Gastric Bypass (RYGB) or Biliopancreatic Diversion (BPD) offer the best chance for long-term diabetes remission (>60% at 8 years). Adjustable Gastric Banding is less effective for diabetes remission (45.6%) despite weight loss. Patients should prioritize procedures involving duodenal exclusion if T2D remission is a primary goal.

High-sensitivity ELISA assays are required to detect changes in fasting insulin following lifestyle interventions, as standard automated immunoassays (e.g., Immulite 2000) fail to capture these treatment-induced improvements.

If you are tracking insulin levels to monitor the effectiveness of diet or exercise changes, ensure your lab uses a high-sensitivity ELISA assay. Standard automated immunoassays may report normal or unchanged levels even if your insulin has significantly improved, leading you to believe your lifestyle changes are ineffective when they are not.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or lipid profiling) to predict whether you will lose weight or improve insulin sensitivity through exercise or diet. These tests may tell you your current risk level, but they cannot tell you if a specific intervention will work for you. Monitor actual physiological changes using high-sensitivity insulin assays if possible.

There is no significant evidence that total fat intake or protein intake interacts with polygenic risk to affect BMI, based on pooled meta-analyses.

Don't rely on simply increasing total protein or total fat to manage genetic obesity risk. The evidence suggests that the specific type of fat (omega-3 vs. trans/SFA) is the key dietary lever, not the total amount of protein or fat.

High intake of dietary fructose (common in Western diets) metabolically rewires innate immunity by increasing mTORC1 activity and IL1B expression in monocytes/macrophages, thereby promoting a pro-inflammatory state and reducing metabolic flexibility.

If you consume a diet high in processed foods containing corn syrup or high-fructose ingredients, you may be inadvertently keeping your immune system in a state of low-grade alert. This happens because fructose pushes immune cells to prioritize inflammatory signaling over metabolic flexibility. Reducing processed fructose intake can help restore normal immune metabolic function.

Obesity and the associated accumulation of bone marrow adipocytes disrupt normal hematopoiesis and immune function by creating a pro-inflammatory environment mediated by TLR4 activation, leading to impaired immune responses and increased morbidity/mortality during infections.

Obesity is not just a metabolic issue; it biologically alters your bone marrow environment. Excess fat in the marrow drives chronic inflammation and impairs the production and function of immune cells, making infections more dangerous. Managing weight can help restore normal immune niche function.

Performing 1 or 2 sets of 3-4 repetitions at 55-75% of 10RM as a specific warm-up provides no performance benefit over no warm-up for resistance-trained individuals performing multiple sets to failure at ~10RM loads.

If you are training with moderate weights (around 10 reps max) and doing multiple sets to failure, you likely do not need a specific warm-up. Skipping it saves 2-5 minutes per exercise without hurting your performance. However, if you are lifting very heavy (1-3RM) or are concerned about injury, you may still want to warm up. Listen to your body, but don't feel obligated to warm up if it's just for performance gains at moderate loads.

Training at longer mean muscle lengths does not produce greater regional muscle hypertrophy compared to shorter mean muscle lengths when using typical contrasts in resistance training.

You do not need to train through a full range of motion to maximize muscle growth. Partial reps performed at long muscle lengths (lengthened partials) are just as effective as full reps for hypertrophy. Focus on consistency and volume rather than forcing full depth if it causes joint pain or technical breakdown.

Postprandial administration of para-tyramine-O-sulphate (pTOS) acts as a conserved anorexigenic gut-brain signal that suppresses food intake and body weight in mice by activating ventromedial hypothalamus (VMH) neurons, without affecting energy expenditure or gastric emptying.

This research identifies pTOS, a metabolite produced by gut bacteria from dietary tyrosine, as a natural signal that tells your brain to stop eating. In mice, supplementing with pTOS reduced food intake and body weight without changing how much energy they burned or how fast their stomach emptied. The effect works by activating specific neurons in the hypothalamus. While human studies show pTOS levels rise after meals, the clinical application for weight loss is still in early stages, particularly for those with diabetes.

Weight stigma and discrimination act as independent social determinants of obesity that increase adiposity through biological stress pathways (glucocorticoid activity) and behavioral coping mechanisms, regardless of individual health behaviors.

Recognize that stress from discrimination can biologically and behaviorally contribute to weight gain, independent of your personal choices. Addressing this requires systemic changes and supportive environments, not just individual willpower. Healthcare providers should screen for discrimination exposure and address stigma to improve health outcomes equitably.